Fineline Cube

Follow:
14778 Articles
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
CompanyDeals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial
CompanyDrug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
CompanyDrug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
CompanyDrug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

CStone Pharmaceuticals' Sugemalimab Wins UK Approval for NSCLC Treatment
CompanyDrug

CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment

Dizal Pharmaceutical's Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
Company

Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
Company

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments
CompanyDeals

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
CompanyDeals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound